Lennox Int'l Boosts FY22 Outlook; Q3 Adj. EPS Meets Estimates, Revenues Top

RTTNews | Před 929 dny
Lennox Int'l Boosts FY22 Outlook; Q3 Adj. EPS Meets Estimates, Revenues Top

(RTTNews) - While reporting financial results for the third quarter on Thursday, Lennox International Inc. (LII) raised its earnings and revenue growth guidance for the full-year 2022.

For fiscal 2022, the company now projects earnings and adjusted in a range of $13.80 to $14.20 per share on revenue growth of 12 to 15 percent.

Previously, the company expected earnings and adjusted in a range of $13.80 to $14.50 per share on revenue growth of 10 to 15 percent.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $14.22 per share on a revenue growth of 11.5 percent to $4.67 billion for the year. Analysts' estimates typically exclude special items.

"We are building turnaround momentum in our Commercial business and are going to invest in a new commercial factory to help alleviate ongoing manufacturing capacity constraints," said CEO Alok Maskara.

For the third quarter, net income increased to $141.9 million or $3.99 per share from $126.3 million or $3.41 per share in the prior-year quarter.

Excluding items, adjusted earnings for the quarter was $4.10 per share, compared to $3.40 per share in the year-ago quarter.

Net sales for the quarter grew 17 percent to $1.24 billion from $1.06 billion in the same quarter last year.

The street was looking for earnings of $4.10 per share on net sales of $1.23 million for the quarter.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

Značky : LII
read more
Lennox Int'l Guides FY23 In Line With Estimates

Lennox Int'l Guides FY23 In Line With Estimates

Ahead of its 2022 Investor Day in New York City later on Wednesday, Lennox International Inc. (LII) initiated its 2023 financial guidance and long-term financial targets for 2026.
RTTNews | Před 881 dny
Bayer Q1 Results Down, Sees Pharma Results At Top End Of View; Stock Gains

Bayer Q1 Results Down, Sees Pharma Results At Top End Of View; Stock Gains

Bayer AG on Tuesday confirmed its currency-adjusted 2025 targets after reporting lower earnings in its first quarter with slightly lower sales. The quarterly results reflected weak results in the Crop Science Division, despite growth in Pharmaceuticals and Consumer Health segments. Shares of the Pharmaceutical and life sciences major were gaining around 6 percent on the XETRA in Germany.
RTTNews | Před 24 minutami